Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 825) with type 2 diabetes and hypertension (mean seated systolic blood pressure [SBP] 130–159 mmHg and diastolic blood pressure [DBP] 80–99 mmHg) were randomized (double blind) to 10 mg or 25 mg empagliflozin or placebo once daily for 12 weeks. RESULTS: At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP (ambulatory blood pressure monitoring [ABPM]) was −3.44 mmHg (95% CI −4.78, −2.09) with 10 mg empagliflozin and −4.16 mmHg (−5.50, −2.83) with 25 mg empagliflozin (both P < 0.001). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP (ABPM) was −1.36 mmHg (95% CI −2.15, −0.56) with 10 mg empagliflozin and −1.72 mmHg (95% CI −2.51, −0.93) with 25 mg empagliflozin (both P < 0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was −0.62% (95% CI −0.72, −0.52) (−6.8 mmol/mol [95% CI −7.9, −5.7]) with 10 mg empagliflozin and −0.65% (95% CI −0.75, −0.55) (−7.1 mmol/mol [95% CI −8.2, −6.0]) with 25 mg empagliflozin (both P < 0.001). Empagliflozin was well tolerated. One patient on placebo and one patient on 10 mg empagliflozin reported events consistent with volume depletion. CONCLUSIONS: Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EMPA-REG BP trial, empagliflozin reduced mean 24 hour ambulatory systolic BP by approximately 3-4 mmHg after 12 weeks, 16 with consistent reductions irrespective of the number of background BP lowering drugs.17”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [16]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · cited 1×
“Randomized controlled trials have shown reductions in major cardiovascular events when SBP was lowered to ,150 mmHg and DBP was lowered to # 85 mmHg in patients with diabetes (23,24).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Cited by
Items 401–500 of 505
SGLT2 Inhibitors for Treating Diabetes
McKay, G. A., & Livingstone, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-43296-0_2 · Cited by 2
Towiargi, R., Fetyani, L., Aljahdali, N., Alnofeie, A., Alnoamy, Y., Ghandorah, R., Abduljawad, A., Alharbi, N., Alghanmi, A., & AlButi, H. (2022) · Cureus · doi:10.7759/cureus.33070 · Cited by 2
Kubica, J., Kubica, A., Grąbczewska, Z., Stróżecki, P., Adamski, P., Brymora, A., Donderski, R. Ł., Fabiszak, T., Flisiński, M., Gajda, R., et al. (2023) · Medical Research Journal · doi:10.5603/mrj.97187 · Cited by 2
Tadić, M., & Cuspidi, C. (2024) · Cardiology Discovery · doi:10.1097/cd9.0000000000000114 · Cited by 2
Rapport 24-09. Changement de paradigme dans les maladies cardio-néphro-métaboliques
Reach, G., & Jaffiol, C. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.10.002 · Cited by 2
Chung, C., Lu, H., Chung, M., Wu, L., Huo, C., Kuo, L., Liu, C., & Chuu, C. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040260 · Cited by 2
“51 In contrast, SGLT2is demonstrated greater antihypertensive effects, lowering systolic blood pressure and diastolic blood pressure by 4.44 mm Hg and 2.15 mm Hg. 51 Canagliflozin, 50,52 dapagliflozin, 53 and empagliflozin 54 all demonstrated notable antihypertensive effects.”
InfluentialSodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Steinberg, H. O. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1168687 · Cited by 2
Alkagiet, S., & Τζιόμαλος, Κ. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i5.150 · Cited by 2
Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints
Laffin, L. J., & Bakris, G. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.006 · Cited by 2
Patil, T., Halsey, E., Kaur, A., Minchak, J., Hobson, J., & Eppes, D. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01226-7 · Cited by 2
Cahyadi, A., & Jimeno, C. (2018) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.1984fbf2de · Cited by 2
Posch, M. G., Walther, N., Ferrannini, E., Powell, D. R., Banks, P. L., Wason, S., & Dahmen, R. (2022) · doi:10.2337/figshare.20069063 · Cited by 2
Changing the Landscape of Hypertension Management With SGLT2i
Bilić-Čurčić, I., Ninčević, V., Canecki-Varžić, S., Prpić-Kriẑevac, I., Ahić, J. M., & Mihaljević, I. (2022) · Southeastern European medical journal · doi:10.26332/seemedj.v6i1.247 · Cited by 1
Prescription Patterns for Empagliflozin among Adults with Diabetes Mellitus in Dhaka, Bangladesh
Shill, D. K., Jahan, S., Reza, M. S., Shohan, S. M., & Rajbangshi, J. C. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i46b32945 · Cited by 1
In Vitro Cytotoxic, Genotoxic, Embryotoxic and Oxidative Damage Potentials by Empagliflozin
Çadırcı, K., Türkez, H., Tozlu, Ö. Ö., Yapça, Ö. E., Bayrak, M., Emsen, B., & Mardinoğlu, A. (2024) · Biology Bulletin · doi:10.1134/s1062359023603919 · Cited by 1
“blood pressure and body weight (Roden et al., 2013; Kovacs et al., 2014; Häring et al., 2014; Tikkanen et al., 2015).”
Lora-Escobar, S. J., Francisco, L. R.-D., López-Feijoo, M., Santos‐Ramos, B., Bellido, V., Mejía, R. M. C., & Acosta-García, H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/3733178 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Rashed, E. R., Sundaravel, S., & Ortega–Legaspi, J. (2025) · Hearts · doi:10.3390/hearts6040032 · Cited by 1
“The EMPA-REG BP investigators trial showed significant BP lowering in addition to glycemic control in diabetic patients treated with empagliflozin [90].”
Hypertension in Chronic Kidney Disease: Guidelines and Therapies
Colbert, G. B., Gaddy, A. R., Anandh, U., & Lerma, E. V. (2025) · Indian Journal of Nephrology · doi:10.25259/ijn_677_2025 · Cited by 1
Kosari, A., Shahinfar, H., Rostampour, K., Mirhosseini, S. G., & Soltani, S. (2026) · Food & Function · doi:10.1039/d5fo03679h · Cited by 1
Omrani, M. A., Baskaran, B. S., Sadeghi, H., Ahmadi, F., Eddin, L. E., Jafari, A., & Muanda, F. T. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2641874 · Cited by 2
Navami, K. S., Thomas, C., & Basutkar, R. S. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.03.008 · Cited by 1
Molecular Mechanisms and Clinical Applications of SGLT2 Inhibitors in Cardiovascular Diseases
Ma, C., Yang, P., Du, R., Yang, S., & Xu, Z. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10794-4 · Cited by 1
“EMPA-REG BP demonstrated that empagliflozin (10/25 mg daily) substantially lowered 24-hour ambulatory systolic and diastolic pressures in hypertensive T2DM subjects (baseline seated SBP: 130– 159 mmHg; DBP: 80–99 mmHg) [ 59].”
To overcome two diseases with one pill
Mogi, M., & Horiuchi, M. (2016) · Hypertension Research · doi:10.1038/hr.2016.3 · Cited by 1
Bloch, M. J. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.01.001 · Cited by 1
Role of Sodium Glucose Co-Transporter-2 Inhibitors in Pre-diabetes and Their Extra-glycemic Effects
Ahmadieh, H., Ghazal, N., & Azar, S. T. (2016) · International Archives of Medicine · doi:10.3823/2129 · Cited by 1
“Despite being a co-primary end point, there was a significant reduction in 24-h systolic and diastolic blood pressures; 4 and 2 mmHg respectively, lower than placebo at the high empagliflozin dose (25mg) [66].”
BackgroundUnpuzzling the Comorbid Type 2 Diabetes and Hypertension-Related Cognitive Dysfunction and Stroke
Sebastião, I., Candeias, E., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2017) · Springer series in translational stroke research · doi:10.1007/978-3-319-45345-3_31 · Cited by 1
Amelioration of arterial pressure lability: an unmissable target for diabetes management
Tanaka, A., & Node, K. (2017) · Hypertension Research · doi:10.1038/hr.2017.35 · Cited by 1
Empagliflozin: an exciting prospect in the treatment of diabetes
Srinivas, K., George, M., & Sriram, D. K. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20175669 · Cited by 1
“001).(9) The safety, tolerability, pharmacokinetics and pharmacodynamics of 10, 25, 100mg of empagliflozin or placebo was evaluated in T2DM patients for 28 days.”
MethodMazur-Mucha, M., & Chrostowska, M. (2019) · Choroby Serca i Naczyń · doi:10.5603/chsin.2019.0035 · Cited by 1
Alicic, R. Z., & Tuttle, K. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00037-8 · Cited by 1
Babic, M., & van der Giet, M. (2021) · Dialyse aktuell · doi:10.1055/a-1557-3924 · Cited by 1
“[30] Tikkanen I, Narko K, Zeller C et al.”
BackgroundArioglu‐Inan, E., & Kayki‐Mutlu, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00162-6 · Cited by 1
Inserra, F., Forte, E. H., Elbert, A. E., Waisman, G. D., & Castellaro, C. (2023) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v57i3.728 · Cited by 1
Novel Potential Drug Interactions with Bisoprolol in Hospitalized Acute Coronary Syndrome Patients
Okda, S. M., Kassem, A. B., Amrawy, A. M. E., Salahuddin, A., Elonsy, S. M., & El‐Bassiouny, N. A. (2024) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2024.247704.1962 · Cited by 1
New Antidiabetic Agents for the Treatment of Heart Failure in Hypertensive Patients
Nilsson, P. M., Holm, H., & Magnusson, M. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_23 · Cited by 1
Involvement of Cholinergic and Cyclooxygenase Pathways in the Diuretic Effects of Rosmarinic Acid
Macarini, A. F., Mariano, L. N. B., da Silva, R. D. C. V., Corrêa, R., & de Souza, P. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401634 · Cited by 1
Monami, M., Dicembrini, I., & Mannucci, E. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0922-5 · Cited by 1
Pitta, F. G. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2024.tde-17062025-165052 · Cited by 1
Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk
Liakos, A., Bekiari, E., & Τσάπας, Α. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0503-8
Empaglifozin and the reduction of risk of death in a high cardiovascular risk population
Moreira, Í. C., Bernardo, G. P., de Lima, D. S. B., Carneiro, C. B. R., Ribeiro, D. L. S., de Sá, M. C. F., de Macedo, M. J., Moreira, P. P. C., Araújo, V. L., de Alencar, J. N., et al. (2016) · International Archives of Medicine · doi:10.3823/2000
Cardiovascular safety of SGLT2 inhibitors
Gumprecht, J. (2016) · Clinical Diabetology · doi:10.5603/dk.2016.0007
Hypertension in type 2 diabetes: impact of glucose-lowering medications
Krentz, A. J. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000100
Katsenos, V., Kostev, K., & Kruppert, S. (2016) · Monitor Versorgungsforschung · doi:10.24945/mvf.03.16.1866-0533.1961
Diabetes mellitus – diagnostische und therapeutische Strategien
Sabia, R., & Wagner, M. (2017) · Gastroenterologie up2date · doi:10.1055/s-0043-104464
“Insgesamt scheint demnach die Blutdrucksenkung bei SGLT-2-Inhibitoren ein Klasseneffekt zu sein [15,16].”
BackgroundSaad, M., Gomceli, U., Ravi, P., Lacoste, A. G., Shah, N., & Vittorio, T. J. (2018) · Drugs in Context · doi:10.7573/dic.212549
Miskelly, M. G. (2018) · Ulster University Research Portal (Ulster University)
Neue Therapien der Herzinsuffizienz mit reduzierter Ejektionsfraktion
Langhammer, R., & Wachter, R. (2021) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-021-9806-x
Ali, H. H., Mahmood, N. M. A., & Hussain, S. A. (2021) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v1i.29
“2015 [17] 3-month RCT, double-blind trial; n=825 subjects 100 or 25mg EPG vs.”
MethodSewage sludge treatment by membrane anaerobic system (MAS)
Musliha, M. (2010) · UMP Institutional Repository (Universiti Malaysia Pahang)
Kramer, H., & Navaneethan, S. D. (2019) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2019.18.4.6
SGLT-2 Inhibitors: Drug Selection by Means of the System of Objectified Judgement Analysis Method
Janknegt, R., Reinders, M., & Bianchi, R. (2021) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2021.05.0750
Aschner, P. J. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727299606.793538292
Vijay, S. (2019) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000218
Sarker, A., Ramesh, A. S., Tello, C. M., Jamil, D., Tran, H. H.-V., Mansoor, M., Butt, S. R., Satnarine, T., Ratna, P., & Hamid, P. (2022) · Cureus · doi:10.7759/cureus.29069
“conducted an RCT study using empagliflozin in T2DM patients with hypertension [24].”
BackgroundMethodInfluentialSGLT 2 Inhibitors and Hypertension: Mild but Effective. What can we expect ?
Ivanović, B. (2022) · Journal of Cardiology & Cardiovascular Therapy · doi:10.19080/jocct.2022.18.555977
Karahan, A., Ateş, İ., Kalkan, E. A., İnan, O., & Şahiner, E. S. (2023) · Ankara City Hospital Medical Journal · doi:10.5505/achmedj.2023.72792
CARDIOLOGIA EM FOCO: PREVENÇÃO, DIAGNÓSTICO E TRATAMENTOS ATUAIS
Almeida, A. B., & Horevicht, C. M. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809
ESTRATÉGIAS ATUAIS PARA A PREVENÇÃO E O TRATAMENTO DA HIPERTENSÃO
Almeida, A. B., Pontes, B. B., Gioia, L. N., & Rangel, V. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809p11
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00039-6
Gohlisch, C. (2023) · Nephrologie aktuell · doi:10.1055/a-2128-3023
“Die Blutdruckreduktion in der Lang-zeit-Blutdruck-Messung scheint sich dabei systolisch im Bereich zwischen 4–6 mmHg zu befinden [30,31].”
BackgroundFeitosa, M. P. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-29112023-130832
Drapkina, O. M., Блохина, А. В., Borisova, A. L., Bukaeva, A. A., Voshev, D. V., Garbuzova, E. V., Dzhioeva, O. N., Drozdova, L. Y., Олеговна, Е. С., Ershova, A. I., et al. (2023) · doi:10.15829/ropniz-d95-2023
c. Part III: Treatment with Antidiabetes Drugs—Effects on Blood Pressure and Central Hemodynamics
Nilsson, P. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00011-8
Metabolic and Renal Outcomes of Empagliflozin among Emirati Patients with Type 2 Diabetes
Aburuz, S. (2024) · Journal of Pharmacology and Drug Delivery · doi:10.59462/3071-2335.2.1.104
Pradhan, S., Kalanski, S., Tintut, Y., & Demer, L. L. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000942
Bednarczyk, P., Chodak, I., Chodak, W., Czyczerska, M., Klimek, M. G., & Lechowski, S. (2024) · Quality in Sport · doi:10.12775/qs.2024.23.54635
Evaluating Use of Empagliflozin for Diabetes Management in Veterans With Chronic Kidney Disease
Williams, C. D., & Bailey, B. (2024) · Federal Practitioner · doi:10.12788/fp.0524
“6,7,8 Limitations This study had a retrospective study de-sign, which resulted in missing information for many patients and higher rates of exclusion.”
Denda, N., Maletin, N., Atanasković, M., Vučković, B., & Rašković, A. (2024) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj2403483d
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Hypertension measurement methods and differential diagnosis
Kaya, B. (2025) · Scientific reports in medicine. · doi:10.37609/srinmed.48
HIPERTENSÃO E DOENÇAS ASSOCIADAS COMO DESAFIO TERAPÊUTICO
de Souza, R. N. S. N. (2025) · EPITAYA eBooks · doi:10.47879/ed.ep.2025820p482
Zhu, X., Lin, C., Li, Z., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70052
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Popp, V. O. (2025) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2025.tde-09092025-143515
Wahiduzzaman, M., Yasmin, A., Hossain, M. S., Dhar, R., & Haider, M. Z. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20253934
高血圧症合併2型糖尿病患者におけるDPP4-阻害薬からSGLT2阻害薬ルセオグリフロジンへの切り替えによる夜間血圧・脈拍への影響
亀田, 玲. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.14943/doctoral.k14989
Ингибиторы SGLT2-обоснование и перспективы применения при ХСН.pdf
Doe, J. (2020) · Figshare · doi:10.6084/m9.figshare.12360779
(n.d.) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
(n.d.) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
Manucha, W. A. F., Ferder, L., Jawerbaum, A., & Choi, M. R. (2023) · Conicet
SGLT2-estäjien vaikutus verenpaineeseen tyypin 2 diabeetikoilla.
Huttunen, N. (2020) · UTUPub (University of Turku)
КАРДИОПРОТЕКТИВНЫЙ ПОТЕНЦИАЛ ИНГИБИТОРОВ НАТРИЙ-ГЛЮКОЗНОГО КОТРАНСПОРТЕРА (ФОКУС НА ЭМПАФЛИФЛОЗИН)
Самижонович, С. И., И.Т., М., & В.В., Ф. (2021) · Complex Issues of Cardiovascular Diseases
Visram, A. (2021) · TSpace (University of Toronto)
Choi, S.-B. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.010
Fakih, W. (2022) · theses.fr (ABES) · doi:10.70675/46370e02z71c5z49ccz880azb52e02d7f36c
Riaz, M., Ghanwani, A., Khan, M., Sahjwani, V., Kumar, V., Farooqui, U. F., Gul, H., Said, M., Shah, S., Qazi, M. S., et al. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005130
“These decreases were accomplished without raising heart rate [ 117 ] .”
PERSPECTIVAS ATUAIS E ABORDAGENS MULTIDIMENSIONAIS NO MANEJO DA HIPERTENSÃO ARTERIAL SISTÊMICA
Mariano, M. A., de Souza, A. P., Metidieri, H. T., Abegão, T. C. F., Marques, C. A. M., PEREIRA, M. B. F., & Aliaga, M. A. C. (2026) · EPITAYA eBooks · doi:10.47879/ed.ep.20260415p329
Alyas, J. T., Nielsen, S. F., & Buus, N. H. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004386
Sargis, R. M., Reutrakul, S., Trasande, L., & Nadal, Á. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01635-4
“…sugars, but that also reduce microvascular complications [ 94 – 97 ], address common comorbidities and predisposing factors (e.g., obesity, MASLD, obstructive sleep apnea, hypertension) [ 98 –103], reduce prediabetes-to-T2D progression [ 98 , 104], and improve cardiovascular outcomes [105– 109 ].”
Vergès, B. L., Rouland, A., Bouillet, B., de Barros, J.-P. P., Fourmont, C., Buffier, P., Jourdan, T., Vergas, V., & Duvillard, L. (2026) · Diabetologia · doi:10.1007/s00125-026-06810-6
Jalil, S., Bari, K., Mumtaz, K., Ibrahim, A., Bhatti, T. K., Pothuraju, S., Adam, M., Magon, H. S., Duong, N. K., & Kwo, P. Y. (2026) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000001078
SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney
Zhou, Z., Hang, W., Zhao, R., Jiang, J., Wu, J., & Wang, D. W. (2026) · Bioscience Reports · doi:10.1042/bsr20260150
Eddy, E., Long, B., Sandei, T., & Meyer, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00651-5
Effect Of Sglt2 Inhibitors On Hypretension, In Diabetic And Non-Diabetic Patients
Shalabh Jauhari, S. R., Rai, S., & Jauhari, R. (2023) · Journal of Pharmaceutical Negative Results · doi:10.47750/pnr.2023.14.s03.07
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Yang, Y., Yang, C., Wang, Y., Rawee, P., Cases, A., Leaf, D. E., Vecchio, L. D., Muka, T., Heerspink, H. J. L., Gansevoort, R. T., et al. (2026) · JAMA · doi:10.1001/jama.2026.19921
Metadata
- Authors
- Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J.
- Affiliations
- Helsinki University Hospital (FI)
- Boehringer Ingelheim (Finland) (FI)
- Boehringer Ingelheim (Germany) (DE)
- inVentiv Health Clinical (CA)
- Corresponding author
- Tikkanen, Ilkka
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-30
- Volume
- 38
- Issue
- 3
- Pages
- 420-428
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2138173919
- Cited by
- 468
- References
- 35
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 27 · 2023: 41 · 2022: 39 · 2021: 38 · 2020: 41 · 2019: 50 · 2018: 44 · 2017: 52 · 2016: 53 · 2015: 31 · 2014: 3
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, type 2 diabetes, hypertension, blood pressure reduction, SGLT2 inhibitors, ambulatory blood pressure monitoring, glycemic control, HbA1c, tolerability, adverse events, dose comparison, antihypertensive therapy, renin-angiotensin system blockade
- MeSH terms
- Analysis of Variance, Antihypertensive Agents, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Administration Schedule, Female, Glucosides, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.